Nanoscale materials-based platforms for the treatment of bone-related diseases
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Zhang, Xiaodi a | - |
dc.contributor.author | Koo, Seyoung | - |
dc.contributor.author | Kim, Ji Hyeon | - |
dc.contributor.author | Huang, Xiangang | - |
dc.contributor.author | Kong, Na | - |
dc.contributor.author | Zhang, Liqun | - |
dc.contributor.author | Zhou, Jun | - |
dc.contributor.author | Xue, Jiajia | - |
dc.contributor.author | Harris, Mitchel B. | - |
dc.contributor.author | Tao, Wei | - |
dc.contributor.author | Kim, Jong Seung | - |
dc.date.accessioned | 2024-09-24T06:30:48Z | - |
dc.date.available | 2024-09-24T06:30:48Z | - |
dc.date.issued | 2021-09 | - |
dc.identifier.issn | 2590-2393 | - |
dc.identifier.issn | 2590-2385 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/120588 | - |
dc.description.abstract | Owing to the high density of bone tissue and the complex and highly hierarchical structure, drugs used for the treatment of bone-related diseases are often not effectively concentrated at the site of the lesion. Generally, the therapeutic effect is unsatisfactory, and the long-term use of drugs causes adverse effects. Therefore, it is of great importance to explore nanotherapeutic platforms to improve bone-targeting capabilities and provide controlled release performance on demand to enhance therapeutic effects. This review aims to (1) summarize various types of recently developed nanotherapeutic platforms; (2) present representative material strategies for applying nanoplatforms for treating bone diseases based on a deeper knowledge of the biophysical structure and material-chemical composition of human osteology, and the awareness of disease pathogenesis and progression; and (3) summarize the typical multifunctional systems through a suitable combination of different cues for enhancing the treatment efficacy. © 2021 Elsevier Inc. | - |
dc.format.extent | 38 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | ELSEVIER | - |
dc.title | Nanoscale materials-based platforms for the treatment of bone-related diseases | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1016/j.matt.2021.05.019 | - |
dc.identifier.scopusid | 2-s2.0-85122628619 | - |
dc.identifier.wosid | 000702820600007 | - |
dc.identifier.bibliographicCitation | MATTER, v.4, no.9, pp 2727 - 2764 | - |
dc.citation.title | MATTER | - |
dc.citation.volume | 4 | - |
dc.citation.number | 9 | - |
dc.citation.startPage | 2727 | - |
dc.citation.endPage | 2764 | - |
dc.type.docType | 정기 학술지(Review) | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Materials Science | - |
dc.relation.journalWebOfScienceCategory | Materials Science, Multidisciplinary | - |
dc.subject.keywordPlus | RHEUMATOID-ARTHRITIS | - |
dc.subject.keywordPlus | STEM-CELLS | - |
dc.subject.keywordPlus | SCAFFOLDS | - |
dc.subject.keywordPlus | DELIVERY | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | NANOPARTICLES | - |
dc.subject.keywordPlus | RELEASE | - |
dc.subject.keywordAuthor | 2D nanomaterial | - |
dc.subject.keywordAuthor | arthritis | - |
dc.subject.keywordAuthor | bone cancer | - |
dc.subject.keywordAuthor | bone fracture | - |
dc.subject.keywordAuthor | nanoparticle | - |
dc.subject.keywordAuthor | osteoporosis | - |
dc.subject.keywordAuthor | scaffold | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S2590238521002381?pes=vor | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
55 Hanyangdeahak-ro, Sangnok-gu, Ansan, Gyeonggi-do, 15588, Korea+82-31-400-4269 sweetbrain@hanyang.ac.kr
COPYRIGHT © 2021 HANYANG UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.